IMW 2019 | Does maintenance therapy increase overall survival in myeloma?
Andrew Spencer, David Siegel, Mohamad Mohty and Philip McCarthy
• 13 Sep 2019
Lenalidomide is typically used as maintenance therapy to increase chances of progression-free survival. However, clinicians have a divided opinion on its necessity, due to the relatively small range of therapeutics available to patients at the time of relapse. Here, Mohamad Mohty, MD, PhD, University Pierre & Marie Curie, Paris, France, is joined by Philip McCarthy, MD, of University at Buffalo, Buffalo, NY, Andrew Spencer, MBBS, FRACP FRCPA, DM, of Alfred Hospital, Monash University, Melbourne, Australia, and David Siegel, MD, PhD, of the John Theurer Cancer Center, Hackensack, NJ, to debate whether maintenance therapy is still a valuable avenue.
